Weekly ReportJun 2–8, 2026
Sepsis, week 23 edition
We read 178 papers and selected 3.
Summary
This week’s sepsis literature highlights mechanistic discoveries that nominate new immune-termination and neuroinflammatory targets, and clinical studies that immediately affect practice: (1) a proteasomal regulator (Zfand5) that terminates TLR3/4–TRIF signaling and necroptosis; (2) microglial galectin‑3 driving hippocampal circuit dysfunction in sepsis-associated encephalopathy with reversal by a clinical-stage inhibitor; and (3) prospective evidence that <1-hour antibiotics lower in‑hospital mortality in neutropenic sepsis. Together these papers span target identification, translational therapeutics, and actionable care-process improvements.
Selected Articles
1. Zfand5 terminates TLR3/4 signaling and necroptosis by targeting TRIF to the proteasome for degradation.
Preclinical mechanistic work identifies Zfand5 as a proteasomal shuttling factor that bridges polyubiquitinated TRIF to the proteasome, terminating TLR3/4-driven inflammatory and type I interferon signaling and limiting TRIF-dependent necroptosis. Zfand5 deficiency worsened sepsis phenotypes in mice, nominating the Zfand5–TRIF axis as a tractable immune‑termination node.
Impact: Reveals a previously unrecognized endogenous termination mechanism for TLR3/4 signaling directly relevant to sepsis pathogenesis and provides a concrete target (TRIF turnover) for therapeutic modulation of hyperinflammation.
Clinical Implications: Suggests development of strategies to enhance TRIF turnover or mimic Zfand5 function (small molecules or PROTAC-like agents) to mitigate TLR-driven hyperinflammation in sepsis; human validation required before clinical translation.
Key Findings
- Zfand5 selectively limits TLR3/4-mediated inflammatory and type I IFN signaling by targeting polyubiquitinated TRIF for proteasomal degradation.
- Zfand5 deficiency in mice exacerbates cytokine responses, TRIF-dependent necroptosis, and sepsis severity.
2. Microglial galectin-3 disrupts parvalbumin interneurons and hippocampal synchrony, driving cognitive deficits.
In an LPS-induced sepsis-associated encephalopathy model, microglial galectin‑3 upregulates TLR2 and NLRP3/AIM2 inflammasomes, increases oxidative stress, selectively injures hippocampal parvalbumin interneurons, disrupts theta/gamma synchrony, and impairs memory. Pharmacologic Gal‑3 inhibition (TD139) and chemogenetic reactivation of PV interneurons rescued network synchrony and cognitive deficits, nominating Gal‑3 as a translational target for SAE.
Impact: Connects a defined microglial effector (Gal‑3) to circuit-level dysfunction and cognitive decline in SAE, and demonstrates reversibility with a clinically explored inhibitor—an important bridge from mechanism to potential therapy.
Clinical Implications: Supports early-phase testing of Gal‑3 inhibitors (e.g., inhaled/ systemic TD139) or circuit-targeted neuromodulation for sepsis‑associated encephalopathy, and prompts biomarker studies (CSF/plasma Gal‑3, electrophysiology) for patient selection.
Key Findings
- Microglial Gal‑3 activates TLR2 and NLRP3/AIM2 inflammasomes, increasing oxidative stress in the hippocampus.
- PV interneurons are selectively injured, theta/gamma oscillatory synchrony is disrupted, and memory is impaired; TD139 and PV reactivation rescue these deficits.
3. Impact of Time to Antibiotics on In-hospital Mortality in Neutropenic Sepsis: A Prospective Multicenter Cohort Study.
A prospective multicenter cohort of 942 neutropenic sepsis patients across 20 hospitals found that first-dose antibiotics delivered within 1 hour were associated with lower in‑hospital mortality compared with 1–3 hours or ≥3 hours after presentation, with the greatest benefit in septic shock and hematologic malignancy subgroups. IPTW-adjusted analyses and causal-forest exploration support urgency of antibiotic delivery in this high‑risk phenotype.
Impact: Provides high-quality prospective evidence quantifying a mortality penalty for antibiotic delays specifically in neutropenic sepsis and identifies subgroups (shock, hematologic malignancy, high lactate) most sensitive to timing — immediately actionable for care pathways.
Clinical Implications: Implement process measures to ensure first-dose antibiotics within 1 hour for suspected neutropenic sepsis, prioritize such patients for rapid triage/antibiotic delivery (especially those with shock or hematologic malignancy), and consider lactate to further triage urgency.
Key Findings
- Antibiotic delay ≥3 hours associated with increased in-hospital mortality vs <1 hour (IPTW-adjusted OR 1.50).
- 1–3 hour delays also increased mortality (OR 1.26); effect stronger in septic shock and hematologic malignancy. Elevated lactate was a potential effect modifier.